Achillion Pharmaceuticals, Inc. To Present At Two Upcoming Investor Conferences

NEW HAVEN, Conn., Nov. 4 /PRNewswire/ -- Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will be presenting a corporate overview and update on the Company's clinical programs in HIV and HCV at the following upcoming investment conferences:

* CIBC World Markets Healthcare Conference - Monday, November 7, 2005 at 11:00 am at the Waldorf-Astoria in New York City * Rodman & Renshaw Techvest 7th Annual Healthcare Conference - Wednesday, November 9, 2005 at 2:50 pm at the New York Palace Hotel in New York City About Achillion

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- HIV, hepatitis and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit the company's web site at http://www.achillion.com or call Achillion at 1-203-624-7000.

This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in larger-scale clinical trials and the risk that the company will not obtain approval to market its products.

Achillion Pharmaceuticals, Inc.

CONTACT: Jonas M. Niaura of Achillion Pharmaceuticals, Inc.,+1-203-752-5486; or Kari Watson of MacDougall Biomedical Communications,Inc., +1-508-647-0209, kwatson@macbiocom.com

Back to news